MultiCASE
MultiCASE is a privately held Ohio-based software company that develops proprietary QSAR machine-learning platforms for in silico chemical toxicity prediction, serving pharmaceutical companies for ICH M7 mutagenicity compliance, nitrosamine evaluation, and drug safety regulatory submissions.
- Company typePrivate
- Founded1996
- HeadquartersBeachwood, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What MultiCASE does
MultiCASE is a privately held US software company headquartered in Mayfield Heights, Ohio, specializing in computational toxicology and in silico chemical safety assessment. Founded in 1996 according to firmographic records, the company develops proprietary QSAR (Quantitative Structure-Activity Relationship) modeling software that uses machine learning to predict chemical toxicity endpoints from molecular structure, primarily serving pharmaceutical companies for drug safety evaluation, regulatory submissions, and chemical hazard screening.
The product portfolio centers on three software platforms: CASE Ultra, a desktop application for in silico toxicity prediction and risk assessment; QSAR Flex, a flexible QSAR modeling platform that was transitioned to a web-accessible application in 2026; and META Ultra, a meta-analysis tool for integrating multiple toxicity prediction methods and curated data sources. Alongside the software, MultiCASE provides specialized assessment services covering ICH M7 mutagenicity compliance, nitrosamine carcinogenicity evaluation, and early-stage research screening. The technology stack uses proprietary QSAR models with original research underway on LLM-assisted expert review of bacterial mutagenicity predictions under ICH M7.
MultiCASE generates revenue primarily through recurring software licensing of its proprietary platforms to enterprise customers in pharmaceutical and chemical safety, operating a direct enterprise field-sales motion with free trial offers and supplementing US direct sales with a network of distribution partners covering Brazil, China, India, Japan, Korea, Mexico, and Latin America. Pricing is not publicly disclosed. The firm is identified as a key player in the global Computational Toxicology Solutions market, operating alongside larger peers including Instem (Leadscope), Lhasa Limited, Inotiv, Simulations Plus, and Schrodinger, with a lean 1-10 employee organizational structure funded organically across nearly thirty years of continuous operation.
MultiCASE firmographics
Firmographics- Name
- MultiCASE
- Legal name
- MultiCASE, Inc.
- Website
- http://www.multicase.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MultiCASE is a privately held Ohio-based software company that develops proprietary QSAR machine-learning platforms for in silico chemical toxicity prediction, serving pharmaceutical companies for ICH M7 mutagenicity compliance, nitrosamine evaluation, and drug safety regulatory submissions.
- Ownership category
- akta.pro rank
MultiCASE industry classification
Industry- Product category
- Computational Toxicology Software
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)
- akta.pro secondary industries
- Pharmacovigilance & Drug Safety Software (HLAGAJAK), Method Development & Validation (ICH/USP) (HLAGADAB), Genetic Toxicology (Ames/Micronucleus/Comet) (HLAGAFAE)
Keywords
Where MultiCASE is headquartered
LocationHeadquarters
- HQ city
- Beachwood
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MultiCASE business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Licensing: MultiCASE generates revenue through licensing its proprietary software products including CASE Ultra, QSAR Flex, and META Ultra. These are offered as desktop and web-based applications for in silico toxicity evaluations and chemical safety assessment.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
MultiCASE product offering
Product offeringCore offering
MultiCASE develops and licenses proprietary software for in silico toxicity prediction and chemical safety assessment used by pharmaceutical and chemical safety organizations. Its portfolio includes three core software products — CASE Ultra (desktop), QSAR Flex (web-based), and META Ultra (meta-analysis) — built on proprietary QSAR models and AI/ML to predict endpoints such as mutagenicity, carcinogenicity, and bioavailability, with specialized assessment services for ICH M7 compliance and nitrosamine evaluation.
Product overview
MultiCASE provides a software platform for in silico toxicity evaluation and chemical safety assessment. The portfolio consists of three core software products (CASE Ultra, QSAR Flex, and META Ultra) designed to strengthen risk assessment strategies, along with specialized assessment services covering ICH M7 compliance, nitrosamine evaluation, and early-stage research applications. The software utilizes proprietary QSAR models to predict chemical toxicity endpoints for regulatory and pharmaceutical applications.
Differentiator
Problem solved
Functional benefit
Brands
- CASE Ultra: Software for in silico risk assessments and chemical safety evaluation
- QSAR Flex
- META Ultra
Products and services
- CASE Ultra
- QSAR Flex
- META Ultra
- ICH M7 Assessment
- Nitrosamine Evaluation
- Early Stage Research
Companies that use MultiCASE
Customer profileSegments2 records
Ideal customer profiles2 records
MultiCASE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
MultiCASE partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Regional Distribution Partners (Brazil, China, India, Japan, Korea, Mexico, Latin America)minorMultiCASE works with established and dependable distribution partners to support their global user base in Brazil, China, India, Japan, Korea, Mexico and Latin America regions.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
MultiCASE competitors and assessment
Company assessmentBroad incumbents
- Schrödinger: Public computational chemistry and molecular simulation platform company with LiveDesign and broader drug discovery suite. Significantly larger, broader incumbent that includes computational toxicology capabilities adjacent to MultiCASE's niche.
- Simulations Plus: Public company offering broader computational chemistry, PBPK modeling (GastroPlus), and toxicology software (ADMETPredictor). Larger, broader portfolio competitor that overlaps with MultiCASE on QSAR/ADMET prediction.
- Inotiv: Preclinical contract research organization providing toxicology and safety assessment services alongside software-enabled offerings. Listed alongside MultiCASE as a key player in computational toxicology solutions.
Emerging players
- ChemAxon: Cheminformatics platform provider with chemical structure handling, property prediction, and drug discovery software. Adjacent peer serving similar pharma/chemistry customers with overlapping computational chemistry capabilities.
- Exscientia: AI-driven drug discovery company using computational methods for small molecule design. Adjacent peer — listed alongside MultiCASE as a key player; shares AI-in-pharma positioning but focuses on discovery rather than safety assessment.
- MolPort: Chemical compound sourcing and informatics platform. Adjacent to MultiCASE's chemistry-data workflow; serves overlapping pharma/cheminformatics buyer personas but focuses on compound supply rather than toxicity prediction.
Direct peers
- Lhasa Limited: Not-for-profit organization providing in silico toxicology software (Derek Nexus, Sarah Nexus) for ICH M7 mutagenicity and impurity assessment. Direct competitor in the same regulatory toxicology niche with a similar member-funded distribution model.
- Instem (Leadscope): Instem acquired Leadscope, a direct computational toxicology and QSAR software provider. Most directly comparable peer — same in silico toxicology customer base (pharma/regulatory), overlapping product functionality, and same ICH M7 use cases.
- ACD/Labs (Advanced Chemistry Development): Provider of chemistry software including predictive ADMET and toxicity modules for pharma and chemical safety. Comparable peer offering in silico property/toxicity prediction tools to similar enterprise customers.
Regional players
- Toxys: Toxicology-focused CRO offering in vitro and in silico toxicology services including ToxTracker. Comparable in the toxicology services space with EMEA focus; serves overlapping pharma safety assessment customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MultiCASE social profiles
Digital presenceMultiCASE financial estimates
Financial estimateRevenue estimate
Valuation estimate
MultiCASE leadership team
Management profileNumber of profiles
MultiCASE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MultiCASE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MultiCASE
What does MultiCASE do?
MultiCASE develops and licenses proprietary software for in silico toxicity prediction and chemical safety assessment used by pharmaceutical and chemical safety organizations. Its portfolio includes three core software products — CASE Ultra (desktop), QSAR Flex (web-based), and META Ultra (meta-analysis) — built on proprietary QSAR models and AI/ML to predict endpoints such as mutagenicity, carcinogenicity, and bioavailability, with specialized assessment services for ICH M7 compliance and nitrosamine evaluation.
Is MultiCASE a public or private company?
MultiCASE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MultiCASE founded?
MultiCASE was founded in 1996. It employs 1 to 10 people.
Where is MultiCASE based?
MultiCASE is headquartered in Beachwood, United States, in the North America region.
How does MultiCASE make money?
One revenue line is on record: software Licensing.
Who are MultiCASE's main competitors?
Broad incumbents on record are Schrödinger, Simulations Plus and Inotiv. Emerging players are ChemAxon, Exscientia and MolPort. Direct peers are Lhasa Limited, Instem (Leadscope) and ACD/Labs (Advanced Chemistry Development). Toxys is listed as a regional player.
Does MultiCASE have an API?
No public API is recorded for MultiCASE.
What industry is MultiCASE in?
MultiCASE's product category is Computational Toxicology Software. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling, with a secondary code of HLAGAJAK, Pharmacovigilance & Drug Safety Software. Its NAICS code is 334516 and its SIC code is 3826.